|
|
|
|
|
|
Products |
| |
|
| |
During the past 15 years InSight has developed a wide portfolio of Biosimilars manufacturing technologies and products.
The "first generation" of off-patent products developed and commercialized by InSight included:
- Interferon alpha (2a)
- Interferon alpha (2b)
- Interferon beta-1a
- Interferon beta-1b
- EPO
- G-CSF
- GM-CSF
- HGH
Main Focus:
Currently, our focus is on the "second generation" of Biosimilars - monoclonal antibodies.
For more information about our current portfolio please visit our "Biogenrics Products" section.
biogenerics products
|
| |
|
| |
|
|
|
